Angeliki Katsarou, Maria Tzikopoulou, Dimitrios Papadopoulos, Sotiria Palioura, Matthew E Falagas
{"title":"Optic and peripheral neuropathy associated with short and prolonged administration of tedizolid: a review.","authors":"Angeliki Katsarou, Maria Tzikopoulou, Dimitrios Papadopoulos, Sotiria Palioura, Matthew E Falagas","doi":"10.1080/14787210.2024.2448143","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Tedizolid is a novel antibiotic of the class of oxazolidinones. This review evaluates the published literature on the optic and peripheral neuropathy associated with short and prolonged administration of tedizolid.</p><p><strong>Areas covered: </strong>A review of published data from 4 databases was conducted, regarding the development of optic and peripheral neuropathy in patients who received tedizolid for short or prolonged duration. A total of 1,212 records were screened; 33 were included in this review. No peripheral or optic neuropathy cases were reported in 6 randomized controlled trials that studied tedizolid use for a short course. In contrast, 2 cases with optic neuropathy (1 not supported by objective findings) in 87 patients of the prospective studies were identified. Additionally, in a total of 277 patients who participated in the 6 retrospective studies, 9 adverse events related to optic or peripheral neuropathy and 1 case with foot drop in 22 patients of the relevant cases reports were recorded.</p><p><strong>Expert opinion: </strong>The available data suggests that the safety profile of tedizolid is favorable, especially when given for a short time. However, more clinical studies are needed regarding its long-term use, given that the neurotoxicity induced by oxazolidinones may be time and dose-dependent.</p>","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"49-65"},"PeriodicalIF":4.2000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Anti-infective Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14787210.2024.2448143","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/7 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: Tedizolid is a novel antibiotic of the class of oxazolidinones. This review evaluates the published literature on the optic and peripheral neuropathy associated with short and prolonged administration of tedizolid.
Areas covered: A review of published data from 4 databases was conducted, regarding the development of optic and peripheral neuropathy in patients who received tedizolid for short or prolonged duration. A total of 1,212 records were screened; 33 were included in this review. No peripheral or optic neuropathy cases were reported in 6 randomized controlled trials that studied tedizolid use for a short course. In contrast, 2 cases with optic neuropathy (1 not supported by objective findings) in 87 patients of the prospective studies were identified. Additionally, in a total of 277 patients who participated in the 6 retrospective studies, 9 adverse events related to optic or peripheral neuropathy and 1 case with foot drop in 22 patients of the relevant cases reports were recorded.
Expert opinion: The available data suggests that the safety profile of tedizolid is favorable, especially when given for a short time. However, more clinical studies are needed regarding its long-term use, given that the neurotoxicity induced by oxazolidinones may be time and dose-dependent.
期刊介绍:
Expert Review of Anti-Infective Therapy (ISSN 1478-7210) provides expert reviews on therapeutics and diagnostics in the treatment of infectious disease. Coverage includes antibiotics, drug resistance, drug therapy, infectious disease medicine, antibacterial, antimicrobial, antifungal and antiviral approaches, and diagnostic tests.